How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?

In the RxPONDER clinical trial, all premenopausal patients with HR+ HER2-negative breast cancer with 1-3 positive LNs had a benefit from adjuvant chemotherapy regardless of their Oncotype DX RS. Therefore, there would not be a need to send for an Oncotype or Mammaprint. This management would not cha...